Gilead Sciences, Foster City, CA Session: 199. HIV 4: Treatment -Outcomes, Adherence, and Toxicities Saturday, October 11, 2014: 12:30 PM Background. A higher triglyceride (TG) concentration is marginally independently associated with an increased risk of myocardial infarction in the D:A:D study. Patients switched to elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/ TDF) from ritonavir-boosted protease inhibitor (PI + RTV) plus FTC/TDF maintained high rates of virologic suppression at week 48 (94% vs 87%); and, overall had improvement in fasting triglyceride concentrations.
Background. A higher triglyceride (TG) concentration is marginally independently associated with an increased risk of myocardial infarction in the D:A:D study. Patients switched to elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/ TDF) from ritonavir-boosted protease inhibitor (PI + RTV) plus FTC/TDF maintained high rates of virologic suppression at week 48 (94% vs 87%); and, overall had improvement in fasting triglyceride concentrations.
Methods. In the STRATEGY-PI study, fasting lipid parameters were measured at baseline and subsequent study visits. Subgroup analysis by PI examines the change from baseline (mg/dL) in fasting lipids and shifts in proportions of subjects with target lipid parameter by the National Cholesterol Educational Program (NCEP) category. were generally small and not statistically different between groups except for a small increase in HDL (mean: 2 vs -1; p = 0.03) and decrease in total cholesterol (TC)/HDL ratio (mean: -0.2 vs 0.0; p = 0.029) for subjects who switched to EVG/COBI/FTC/TDF from DRV, and decreases in TC (mean: -24 vs 2; p = 0.002) and HDL (mean: -2 vs 6; p = 0.016) for subjects who switched to EVG/COBI/FTC/TDF from LPV. 
